Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels.
| Revenue (Most Recent Fiscal Year) | $306.91M |
| Net Income (Most Recent Fiscal Year) | $-59.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.18 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -17.49% |
| Net Margin (Trailing 12 Months) | -19.26% |
| Return on Equity (Trailing 12 Months) | -10.47% |
| Return on Assets (Trailing 12 Months) | -6.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.80 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.01 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.14 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 410.67M |
| Free Float | 402.62M |
| Market Capitalization | $360.82M |
| Average Volume (Last 20 Days) | 1.23M |
| Beta (Past 60 Months) | 1.98 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.96% |
| Percentage Held By Institutions (Latest 13F Reports) | 22.25% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |